about
Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk managementExamining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England.Utilisation of extended release quetiapine (Seroquel XL™): Results from an observational cohort study in England.The 9th Biennial Conference on Signal Detection and Interpretation in Pharmacovigilance.Non-medical opioid use in youth: Gender differences in risk factors and prevalence.The association between insomnia and prescription opioid use: results from a community sample in Northeast Florida.Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management.Impact of survival bias on opioid-related outcomes when using death as an exclusion criterion.Implications of off-label use: An example from the final results of an observational cohort study on Intrinsa® (testosterone patch).Potential impact of exposure definition when examining non-medical use of prescription opioids among US veterans.Safety of Atrovent(®) CFC-free inhaler: respiratory events reported from an observational cohort study in England.Utilisation and Safety of Deferasirox: Results from an Observational Cohort Study in England.Utilization of fentanyl buccal tablets in England: exploring off-label use reported in a cohort study.Sex differences in patterns of prescription opioid non-medical use among 10-18 year olds in the USSystematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk managementSex differences in peer and parental risk factors for non-medical use of prescription opioids in youthA Longitudinal Analysis of the Substance Abuse, Violence, and HIV/AIDS (SAVA) Syndemic among Women in the Criminal Justice SystemPower of the Peer and Parent: Gender Differences, Norms, and Nonmedical Prescription Opioid Use Among Adolescents in South Central KentuckyOne Step at a Time: A Latent Transitional Analysis on Changes in Substance Use, Exposure to Violence, and HIV/AIDS Risk Behaviors among Female OffendersFirst Conference on Big Data for PharmacovigilanceSystematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a framework for rapid decision-makingRemdesivir in treatment of COVID-19: A systematic benefit-risk assessment
P50
Q33606022-4A9EDF0E-6D31-4AD5-951F-88119DDD9302Q34051869-2D321652-4694-4FE8-B096-9CC4FD90436AQ34072938-F1027E11-BB5E-4C53-BA2A-061A59E74737Q36698885-DF248A2E-B0F9-46D5-A9B9-8834E5F62881Q40001288-9B6B28F0-0484-4F1D-B3BC-39666BED2572Q40088246-ED29A998-1E52-485D-9080-42D7CF77AA93Q40251900-149F2FD6-95F5-4F8C-883D-44C27B833728Q41996821-D9480AA6-B06C-486B-8105-FB1DB653EDDBQ43160884-C6BA8865-5600-4B8E-A58B-80AD474B4241Q44336413-7E426D3F-C3E7-465E-91DD-2F7FA747E6BDQ44971482-186E062B-C609-4588-BF83-11B71D24ED0EQ45326560-21D81B8A-FA08-47B0-85AA-CAA311687D73Q47616675-07E1D9C9-67B7-4D32-9F6D-5AEDC98D1A39Q47822424-F4B2FA3A-AA48-4C47-8AC2-512E498EC928Q47971051-F8E21171-98E6-486D-A5C5-475D378A02DFQ57479394-D113C7DD-8466-45FB-BBD6-5BE83026651CQ89865207-6F33BE95-BD65-4331-9BBF-3881DD0D3CE6Q90651225-2D545DE3-56DE-40E6-9ABE-3D86D9BF0C1AQ90967729-7266DC01-AEDA-4A16-8AB1-F4E2F9058E55Q91022341-0515FC0D-03A9-40D4-989F-966A29E092B8Q91472736-61652AB0-947F-4E7D-81CC-70110AB0A89AQ91558423-B0B632FA-74CF-4F69-8A64-6C3E871B94FCQ95609022-0AEBA16B-0C85-4576-9387-62E04359B5CFQ95614106-DFA9CB77-BFCA-4CA3-92DD-9AA9EF8FF060
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Vicki Osborne
@en
Vicki Osborne
@nl
type
label
Vicki Osborne
@en
Vicki Osborne
@nl
prefLabel
Vicki Osborne
@en
Vicki Osborne
@nl
P31
P496
0000-0002-3669-6084